Status:
COMPLETED
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.
Lead Sponsor:
Novartis
Conditions:
Conduct Disorder
Eligibility:
All Genders
6-16 years
Phase:
PHASE4
Brief Summary
Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior. This study will investigate the efficacy a safety of oxcarbazepine...
Eligibility Criteria
Inclusion
- History of conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified
- Score \>8 on the Impulsivity Rating Scale
Exclusion
- Other serious medical or psychiatric conditions excluding conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified
- Treatment with antiepileptic medications
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2004
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00154362
Start Date
April 1 2003
End Date
October 1 2004
Last Update
November 24 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.